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It is indeed a pleasure to be here on this auspicious occasion and to speak on the
clinical aspects of the cancer program. I think one might begin by saying that five
years is the conventional period required to evaluate any program in cancer, and it is
not quite five years since passage ofthe act. It is in the nature ofbiomedical research
that the fruits we recognize today have many oftheir roots much more than five years
ago. Nevertheless, there have been a number ofsignificant changes in clinical practice
and clinical viewpoints during the past five years, and collectively I do not think these
can be divorced from the National Cancer Program under the 1971 legislation.
Indeed, it is reasonable to feel that without this federal support many, and probably
most of them, would have been further delayed.
One of the anomalies of the cancer program is that the focus of treatment is still
surgery, yet most ofthe research is going forward in the nonsurgical fields. Probably
the fastest moving field in recent years has been chemotherapy. Five years ago the
treatment ofacute lymphatic leukemia in children was already well advanced through
the efforts of Sidney Farber and many others. Methotrexate had been demonstrated
to be curative in a large percentage ofpatients with chorionepithelioma and had been
tried successfully in Burkitt's lymphoma in Africa.
The treatment of Hodgkin's disease was advancing but much of the experience
with the modern methods developed and emphasized, particularly by Dr. Henry
Kaplan at Stanford, has gone forward during the past five years. We now know that
the results of combined therapy in Hodgkin's disease are incomparably better than
anything we knew about at the time I received my medical education and for many
years thereafter. Just how good these are remains to be determined because of the
long follow-up necessary. It would appear that with combined therapy the vast
majority of Hodgkin's patients will live over five years and there is reason to believe
that many of them can be kept in health for a major part oftheir life expectancy, if
not all of it.
Combined therapy has played an ever increasing role in Wilm's tumor, with
increases in five year survival from the 30 to 40 percent with surgery alone, to the 50
or 60 percent with surgery plus radiation, and to the 70 to 80 percent with surgery,
radiation plus chemotherapy.
The results in neuroblastoma are closely related to the age of onset; the earlier the
age, the better the results. Some good results have been obtained with surgery alone,
but again combined therapy has improved them. A more recent triumph has been in
osteogenic sarcoma, where high doses of methotrexate with citrovorum rescue as
advocated by Djerassi and demonstrated by Frei and his colleagues at the Sidney
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Farber Center have paid off. It is still too soon to know exactly what percentage of
people suffering from this condition will survive five years, or what their ultimate fate
will be. Multiple myeloma and rhabdomyosarcoma have likewise been responsive
and more recently granulocytic leukemia has begun to respond.
All ofthese conditions are by and large highly cellular, rapidly growing tumors and
most of them have in the past brought early death, commonly within a year or two.
Turning to the field of radiology, we have a few advances in therapy. Some years
ago Churchill Davidson in England put special stress on the low oxygen concentra-
tion at the center of tumors and emphasized the degree to which this impaired the
effect ofradiation. He applied hyperbaric oxygenation in the belief that he could soak
the tissues in oxygen sufficiently to increase the sensitivity of the malignant cells to
radiation. He was so convinced of this thesis that he felt it unjustifiable to run a
control series. Had a randomized series been done, his results might have been far
more convincing.
Another approach to the radiation treatment of cells at low oxygen tension is the
use of fast neutrons. Their effect is less influenced by oxygen tension than is the effect
of x-rays. Fast neutrons have been generated by cyclotrons, a number of which are
available from earlier experiments in high energy physics. They can also be generated
by the deuterium tritium technique advocated and developed by Dr. James T.
Brennan at the University of Pennsylvania. The latter technique requires much less
expensive apparatus, but generates only one degree ofintensity ofradiation (about 14
megavolts). Dr. Brennan was able to increase the number of neutrons generated by
using a double source of ions beamed on a common target. In this way the intensity
of the beam was sufficient to keep the treatments within acceptable time limits.
Those generators which depend on cyclotrons are more versatile in that they can be
adjusted to produce rays of varying degrees ofintensity and, depending on the size of
the cyclotron, the flux can be varied more widely also. In spite ofthe promising leads,
fast neutron radiation has not come into wide use. Perhaps its best known trial has
been at Hammersmith under the direction of Dr. Mary Catterall. She has applied it
especially to tumors of the head and neck, and certainly a number ofher results have
been impressive. Her current randomized series had not run long enough to draw
definitive conclusions when last I heard her report.
Radiology has contributed more in diagnosis, perhaps, than in therapy. Here
again, we are dealing with a steady advance, rather than with anything that began in
1971. In 1963, David Kuhl published [1,2] his studies on the application ofcomputer
technology to tomography. He had entered into conversations with a manufacturer
of X-ray equipment to produce the apparatus commercially, but the final decision of
that company was negative. In 1972 Godfrey Hounsfield [3], a British engineer,
persuaded the EMI organization in Great Britain to build such an apparatus, which
resulted in the EMI scanner. This new method for diagnosis of intracranial lesions,
including tumors, has swept the civilized world.
The enlargement of this apparatus to accommodate the whole body has followed
rapidly and several such units are now in place in various major cities in the United
States. They produce a series of sections through the body showing the relative
density of different tissues, including bone, and the relations ofthese shadows to each
other. Computerized axial tomography is a major advance in radiologic diagnosis.
Dr. Kuhl has worked on the application of computer technology to the analysis of
signals from radioactive isotopes and further developments may be expected.
During the past five years the use of radioactive isotopes in diagnosis has been
extended. The use ofthe isotope Iodine'3' and also Iodine'25 in the diagnosis ofgoiter
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is now widespread. Radioactive Gallium has been used both in the diagnosis of
tumors and in the diagnosis of hidden abscesses. Strontium99 has been used in the
study of bone tumors, including metastases, but now seems to be getting displaced a
good deal by Technetium99.
The introduction of opaque media by differential arterial catheterization has
advanced, and the interpretation ofthe angiographs obtained by these techniques has
been further refined. This has been particularly useful in the pancreas where the best
scanning material, radioactive selenomethionine, has proved to be a rather crude
indicator of pancreatic tumors.
One of the fields in which X-ray has been used increasingly in diagnosis is
mammography. Twenty-eight centers have been set up, supported in part by the
National Cancer Institute and in part by the American Cancer Society, for the
diagnosis of early breast cancer. This trial has been reasonably productive. A small,
but definite percentage of patients examined has shown signs suggestive of carci-
noma. This has led to a large number of biopsies, some 20% ofwhich have revealed
carcinoma. Of the carcinomas discovered in this way, less than 25% have had axillary
metastases in those cases in which the axillary contents were removed and submitted
for histologic examination. This compares with 50 to 55% of cases with positive
axillary nodes in most previous series. Since there has been a high degree ofcorrela-
tion between negative axillary nodes and five-year survival, it is reasonable to believe
that a considerable saving of life has been accomplished in this way.
In the course of these studies it was noted that the mammogram was much more
useful in women over the age of 50 than in the younger age group and increasing
concern has arisen regarding the possible carcinogenic influence of the radiation.
Alarm in this matter was touched off by a long-term follow up of women who had
had tuberculosis earlier in life treated by pneumothorax with radiologic control. In a
group of such women it was found that the incidence of breast cancer was five orsix
times as high in the breast on the side where the pneumothorax had been as in the
other breast. This difference was attributed to the increased radiation. In light of
these data and other data, the National Cancer Institute withdrew its recommenda-
tion to continue regular screening mammography in asymptomatic women under 50
and is now concentrating on women over 50.
Another form of radiation which has been utilized to some extent by radiologists,
and to some extent by surgeons, is heat. Radiation ofheat from the body surface has
been measured with accurate instruments and plotted. The principal application has
been in the breast and the resulting plot has been described as a thermogram. In
general, just as inflammation is accompanied by rubor and calor, so increased
infrared radiation will be found not only around abscesses, areas of infection, but
also around tumors. If one can exclude infection on clinicalgrounds, then concentra-
tions of infrared radiation suggest tumorformation and particularly the formation of
malignant tumors. In practice thermography has been quite confusing to the average
clinician and in general, even the radiologists do not like to rely upon it as the sole
indication for biopsy. Many of them, however, do use it as an indicator for earlier
repetition of mammography.
My own attitude toward it is a rather negative one, though my good friend, Dr.
Philip Hodes, when he was Chairman of the Department of Radiology at Jefferson
Medical School, had a number ofexamples in which it had been helpful indiagnosis
and at least one rather convincing one in which it appeared that the diagnosis would
have been missed for a period oftime without it. The phenomenon underlying it is an
interesting one, namely the increased blood flow elicited by malignant tumors.
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photographs and found that within two hours ofsuch a transplant increased infrared
radiation was commonly measurable. Indeed, if increased infrared radiation did not
appear in a reasonably short time, the tumor implant generally did not take. This
phenomenon has been studied in a much more detailed way in recent years by Dr.
Judah Folkman, now the Chief of Surgery at the Boston Children's Hospital. He has
observed the phenomenon in a number of different ways and has sought an agent
which accounts for the increased ingrowth of capillaries which a malignant tumor
seems able to command from the host. He observed that if the implant was simply
transplanted into an isolated organ maintained by perfusion, the implant would only
grow to a very small size (I believe 2 or 3 millimeters), and then remain stationary
because there was no angiogenesis. The viability of the implant could be proved by
transplanting it to an intact host, where it would elicit a vascular response and begin
to grow. He has, ofcourse, been seeking ways of inhibiting this vascular response in
the hope that human tumors likewise could be kept stationary. To my knowledge this
quest has not as yet resulted in methods which are useful in the clinical field.
While the margin of the tumors seems supplied with abundant blood vessels and it
is common to see increased radiation from such areas, the reverse is the case in the
center of the tumor where the vascular supply is commonly deficient. Dr. Harry
LeVeen [4], of the Downstate Medical Center of the University of the State of New
York, has taken advantage of this in the following way: he has generated heat in the
tissues by the application of controlled electromagnetic waves at a rate which they
can be carried off by the normal circulation. Thus, a sufficient flux to generate a
temperature of 1040 Fahrenheit in normal tissues is at times accompanied by the
generation of temperatures of 1100 to 1180 F in the inside of tumor masses. Such
temperatures maintained for an appropriate time are followed by necrosis and
absorption of the products of the necrosis with a reduction in the size ofthe tumor.
The patients reported who had received this treatment were, as one would expect,
advanced cases with metastases and poor prognosis. Dr. LeVeen was encouraged by
the shrinkage of some of the tumors, and by the absence ofliving cells found in the
tumors of patients who came to autopsy orwho had nodules removed surgically after
being shrunk. So far, however, survivals have, for the most part, been briefand the
trials too short for general evaluation.
Turning now to the field of immunotherapy, there have been interesting observa-
tions by Hellstrom and Hellstrom at Seattle on blocking antibodies, particularly in
patients with melanoma. In one striking case, followed by Dr. Ingegard Hellstrom,
the antibodies which blocked tumor cells in culture from being attacked by patients'
lymphocytes suddenly disappeared, with the subsequent destruction of the tumor
cells in vitro by the lymphocytes. At the same time the subcutaneous nodules of the
patient stopped growing and regressed. This seemed to be a clear-cut instance in
which, for reasons unknown, the formation of blocking antibodies was interrupted,
and the body's cellular immune system rapidly reduced the tumor.
Various efforts have been made to augment the patient's immune response. Most
successful has been the use of BCG injected intralesionally in cutaneous and subcu-
taneous melanoma metastases. This has led to regression in many instances. C-
Parvum has similarly been used to stimulate an immune response.
Immunotherapy has been combined with other modes oftherapy and increasingly,
tests are being carried out to test the immune response of the individual with cancer.
General anergy, or a lack of immune response, seems to be a sign that the tumor is
likely not to respond to therapeutic efforts.
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Another use of immune reactions has been in diagnosis where much work has gone
on with CEA (carcinoembryonic antigen), described at McGill University in Mon-
treal by Gold and Freedman, as a diagnostic marker of colon carcinoma. These
authors recognized that this antigen might be positive in certain other malignant
tumors, such as carcinoma of the pancreas. An extensive study was organized by the
American Cancer Society and the Canadian Cancer Society. The results were largely
disappointing. However, the method is of some use in determining prognosis. The
main objective to using it in screening is that it is more regularly positive in advanced
tumors, and infrequently positive in early tumors.
The fact that this particular marker to which Dr. Cole and I both addressed
considerable attention a few years ago proved less valuable than we had hoped does
not mean that some other immunologic marker may not be discovered which will be
of far greater use in the early diagnosis ofcancer. The immunologic methods are so
sensitive that extremely small amounts of characteristic substances can often be
identified, particularly by radioimmunoassay.
As I have already said, there has been comparatively little recent cancer research
support in surgery, even though most primary tumors are treated surgically, and
most five year survivors of cancer have been operated upon as their primary treat-
ment. In spite of this, our perception of the role of surgical excision in cancer
treatment has undergone far-reaching and fundamental change, and much ofthis has
occurred in the past five years. The classical rationale for surgical treatment of
tumors was to operate when they were small so as to remove them entirely before
they had spread. To this end, a large area of surrounding tissue which appeared
normal was removed for insurance and in recognition of the fact that tumors often
extended microscopically considerably beyond changes visible to the naked eye.
It followed that ifa tumor had metastasized, it was not worthwhile to operate on it
beyond doing a biopsy to confirm the diagnosis and to permit the pathologist to
render a prognosis or make the observation on the basis of which others might
present a prognosis.
While many minds have run in the same channel, my own thinking on this subject
was accelerated by the request to deliver the Ewing Lecture at the Maui Meeting of
the James Ewing Society in 1974. I was impressed in that year with a number ofcases
ofcancer which acted peculiarly. There was the young woman with breast cancerwho
developed bone metastases in her second post operative year, yet was surviving and at
work ten years after her operation with the help ofoophorectomy, radiation to areas
of pain, and chemotherapy. She is still alive, though she now has a left supraclavicu-
lar mass and another in the right parietal region. Another patient with a breast
carcinoma went fourteen years without a sign of difficulty only to develop a skin
recurrence above the medial end of her mastectomy scar.
Such experiences seem best explained by a capacity for resistance which enables
the body to hold microscopic and other metastases in check forlong periods oftime.
Accordingly, I asked our tumor registry to look up the cases in which I had
personally done mastectomy for breast carcinoma and obtained the following data:
-The five year results were about the same as had been achieved in many other
series.
-The incidence of axillary node involvement was 55%.
-The average age of the patient was 54 years.
Those patients who had been followed ten years, however, showed that about as large
a proportion of the five year survivors had died in the second five years as had
succumbed in the first five years. We have not, I regret to say, tracked these down to
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establish how many died of other causes. The fact that the series was five years older,
however, would be insufficient to explain a large part of the fall-off. Such information
strongly suggests that much of the so-called "early breast cancer" is really not early,
that the removal of the primary tumor adjusts the tumor-host relationship in favor of
the host, that the five year survival is a relatively poor index of cure in breast
carcinoma, as it has long been known to be in thyroid carcinoma, and that surgery is
to be thought of more as a means of assisting the body's natural resistance to
malignant cells than as a method of completely extirpating a tumor before any of the
cells have spread elsewhere.
If this is indeed the case, one questions the value of the ultraradical procedures, but
one questions even more the rationale of doing nothing once a distant metastasis has
been revealed. During the past five years adjuvant therapy with chemotherapeutic
agents has been tested by the Eastern Cooperative Oncology Group (Dr. Bernard
Fisher, Chairman) and by.Dr. Bonnadonna in Milan, Italy. Dr. Fisher utilized a
single agent at a relatively low dosage which made it more acceptable to patients and
physicians. Patients received L-PAM every six weeks for more than a year. Bonna-
donna used three drugs: Cytoxan, Methotrexate and 5-Fluorouracil. He pushed the
dose often to the limit of tolerance. Both series, Fisher's at two years and Bonnadon-
na's at 18 months, show a far lower incidence of early recurrence than controls. It is
still premature to predict how these series will turn out; it seems reasonable to hope
that there will be an overall extension of survival as counted in the average number of
months per hundred patients.
Questions which are not answered are how great the survival will be, how long it
will last, how the patients will react to other forms of therapy if recurrence super-
venes, and finally, whether the known carcinogenic actions of some of the drugs
involved will become manifest with the appearance of other tumors in the late
survivors. Currently, both series have been quite limited to patients with proven
axillary metastasis. The results of these studies are that surgeons are less convinced
that much is gained by a full radical mastectomy as compared with a modified radical
mastectomy, which leaves a large part or all of the pectoral muscles intact. Some
physicians question whether the lymph nodes should be removed. This is certainly
necessary for staging, and common sense would hardly lead one to leave them behind
since most of them are so easily accessible and since they comprise so small a fraction
of the total lymphatic apparatus of the body.
There is now a deep interest in the interrelationship of nutrition and cancer. This
has several aspects. There is a possibility that some types of food may contain
carcinogens that initiate and/or promote the growth of cancers. That foods can do
this seems almost certain from animal experiments. Thus, aflatoxins occurring in
decaying nuts are potent carcinogens. Likewise some of the Nitroso compounds will
produce nearly a 100% incidence of carcinoma in appropriate strains of rodents
following a single administration of the chemical.
The overall relation of general nutrition to tumor formation is more difficult to
evaluate. It is believed that there is more breast carcinoma among individuals who
are obese; it is known from animal experiments that a tumor-bearing animal will live
longer than its controls if starved. This experiment has recently been repeated with
refinements by Dr. Jeffrey Oram-Smith [5], using controlled intravenous nutrition in
the rat. The tumor-bearing rat does better if it is given amino acids and abundant
calories in the form of glucose even though the rate ofgrowth ofthe tumor is slightly
increased. If it is given the amino acids without glucose, the host dies of starvation
while the tumor grows rapidly. On the other hand, Dr. Edward M. Copeland and
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associates [6] in approaching the problem of the patient undergoing intensive anti-
cancer treatment, has found intravenous nutritive support helpful. He has related this
to the cellular immune response ofthe individual, referring back to the paper of Law,
Dudrick and Abdou [7], in which cellular immune response was augmented by
intravenous hyperalimentation in a series of patients not necessarily harboring
cancer. In Copeland's series of patients, six had positive response to at least one test
for cellular immunity before the onset of treatment. Of the other eleven who were
anergic, all but four converted so that at least one of their tests became positive
following intravenous hyperalimentation. All ofthe positive responses to chemother-
apy in this series occurred among the patients who had a positive test for cellular
immunity before the onset of the treatment or afterwards.
In summary, the cancer program has had important and far reaching effects on
clinical practice. These are most obvious in the field of chemotherapy where some
eleven tumors, formerly almost uniformly fatal, have been shown to respond either to
chemotherapy alone or to combined therapy. In the field of radiation therapy there
have been gains on the equipment front, and there have been exploratory experi-
ments with the use of heat induced differentially within tumors, and there have been
very important advances in radiologic diagnosis, particularly in the field ofcomputer-
ized axial tomography. In immunotherapy there has been much questing and a fair
demonstration of the usefulness of BCG in cutaneous metastases of melanoma.
In surgery there have been no more than modest gains in surgical technique. There
continue to be strong gains in supportive therapy which have permitted some further
extension of the scope of surgery. Most importantly, however, there has been a
profound change in our thinking concerning the role of surgery in the treatment of
cancer and its interrelation with other forms of treatment. There has been an
increasing recognition of the role oflarge tumor masses on the one hand, and oftheir
removal, on the other hand. Thus, surgeons are less and less concerned about the
tumor being operable, meaning that it has not spread, and increasingly of the view
that it is often worthwhile to debulk a tumor in the hope ofenhancing the effective-
ness of other treatments such as chemotherapy.
Thank you.
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